Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics   TOKYO and BASKING RIDGE, N.J. and NEW YORK, Dec. 17, 2018/PRNewswire/ — Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) and AnHeart Therapeutics Inc. (“AnHeart Therapeutics”) announced they have entered into a worldwide exclusive license agreement (“Agreement”) for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor, currently in phase […]

Scroll to top